Axsome Therapeutics, Inc.

This clinical trial is testing whether an experimental medication called AXS-05, which combines dextromethorphan and bupropion, can help adults quit smoking. The study will compare AXS-05 against a placebo and an existing smoking cessation drug, bupropion, to see which is more ef…

This phase 3 trial tests whether solriamfetol, taken once daily, can reduce ADHD symptoms in children aged 6 to under 12. Over 6 weeks, researchers compare the drug against a placebo using a standard rating scale. The goal is to see if solriamfetol is a safe and effective treatme…

This study tests whether solriamfetol, a medication taken once daily, can reduce symptoms of attention deficit hyperactivity disorder (ADHD) in adolescents aged 12 to 18. Over six weeks, participants receive either solriamfetol or a placebo to compare changes in ADHD symptoms. Th…

This Phase 3 trial is testing whether solriamfetol, a drug already approved for sleep disorders, can reduce binge eating episodes in adults with binge eating disorder. About 450 participants will receive either solriamfetol or a placebo daily for 12 weeks. The main goal is to see…

This Phase 3 study tests whether AXS-14 (esreboxetine) can help manage fibromyalgia symptoms like pain and fatigue. About 620 adults with fibromyalgia will take the drug or a placebo daily. The study uses a 'randomized withdrawal' design to see how long the drug's effects last.

This study tests a drug called solriamfetol in adults with major depressive disorder who also struggle with excessive daytime sleepiness. About 508 participants will first receive the drug openly, then some will switch to a placebo to see if the drug helps prevent depressive symp…

This Phase 3 trial tests whether the drug solriamfetol can reduce excessive sleepiness in people with shift work disorder. About 520 adults who work night shifts will take either solriamfetol or a placebo daily for 12 weeks. The study measures how well they stay awake and their o…